Progress in Pediatric Cardiology
Volume 21, Issue 2 , Pages 161-165 , March 2006

Tissue Engineering of heart valves—Immunologic and inflammatory challenges of the allograft scaffold

References 

  1. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89:635–641
  2. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333:11–17
  3. Lupinetti FM, Warner J, Jones TK, Herndon SP. Comparison of human tissues and mechanical prostheses for aortic valve replacement in children. Circulation. 1997;96:321–325
  4. Fann JI, Miller DC, Moore KA, et al. Twenty-year clinical experience with porcine bioprosthesis. Ann Thorac Surg. 1996;62(5):1301–1311
  5. Vongpatanasin W, Hillis D, Lange RA. Prosthetic heart valves. N Engl J Med. 1996;335(6):407–416
  6. Robbins RC, Bowman FO, Malm JR. Cardiac valve replacement in children: a twenty year series. Ann Thorac Surg. 1988;45:56–61
  7. Williams DB, Danielson GK, McGoon DC. Porcine heterograft valve replacement in children. J Thorac Cardiovasc. 1982;85:446–450
  8. Solymar L, Rao PS, Mardini MK, Fawzy ME, Guinn G. Prosthetic valves in children and adolescents. Am Heart J. 1991;121:557–568
  9. Turrentine MW, Ruzmetov M, Vijay P, Bills RG, Brown JW. Biological versus mechanical aortic valve replacement in children. Ann Thorac Surg. 2001;71(suppl 5):S356–S360
  10. Jamieson WR, Rosado LJ, Munro AI, et al. Carpentier–Edwards standard porcine bioprosthesis: primary tissue failure (structural valve degeneration) by age groups. Ann Thorac Surg. 1988;46(2):155–162
  11. Chambers JC, Somerville J, Stone S, Ross DN. Pulmonary autograft procedure for aortic valve disease; long-term results of the pioneer series. Circulation. 1997;96:2206–2214
  12. Simon P, Aschauer C, Moidl R, et al. Growth of the pulmonary autograft after the Ross operation in childhood. Eur J Cardiothorac Surg. 2001;19:118–121
  13. Baskett RJ, Ross DB, Nanton MA, Murphy DA. Factors in the early failure of cryopreserved homograft pulmonary valves in children: preserved immunogenicity?. J Thorac Cardiovasc Surg. 1996;112(5):1170–1178
  14. Stark J, Bull C, Stajevic M, Jothi M, Elliott M, de Leval M. Fate of subpulmonary homograft conduits: determinants of late homograft failure. J Thorac Cardiovasc Surg. 1998;115(3):506–514
  15. Tweddell JS, Pelech AN, Frommelt PC, et al. Factors affecting longevity of homograft valves used in right ventricular outflow tract reconstruction for congenital heart disease. Circulation. 2000;102(19 Suppl 3):III130–III135
  16. Neuenschwandner S, Hoerstrup SP. Heart valve Tissue Eng. Transpl Immunol. 2004;12(3–4):359–365
  17. Schenke-Layland K, Opitz F, Gross M, et al. Complete dynamic repopulation of decellularized heart valves by application of defined physical signals — an in vitro study. Cardiovasc Res. 2003;60(3):497–509
  18. Hoerstrup SP, Zund G, Cheng S, et al. A new approach to completely autologous cardiovascular tissue in humans. ASAIO J. 2002;48(3):234–238
  19. Jockenhoevel S, Zund G, Hoerstrup SP, et al. Fibrin gel — advantages of a new scaffold in cardiovascular Tissue Eng. Eur J Cardio-Thorac Surg. 2001;19(4):424–430
  20. Grabenwöger M, Sider J, Fitzal F, et al. Impact of glutaraldehyde on calcification of pericardial bioprosthetic heart valve material. Ann Thorac Surg. 1996;62:772–777
  21. Schoen FJ, Levy RJ. Bioprosthetic heart valve failure: pathology and pathogenesis. Cardiol Clin. 1984;2(4):717–739
  22. Schoen FJ, Levy RJ. Heart valve anti-mineralization. Eur J Cardiothorac Surg. 1992;6(Suppl I):S91–S94
  23. O'Brien MF, Goldstein S, Walsh S, Black KS, Elkins R, Clarke D. The SynerGraft valve: a new acellular (nonglutaraldehyde-fixed) tissue heart valve for autologous recellularization first experimental studies before clinical implantation. Semin Thorac Cardiovasc Surg. 1999;11(suppl 1):194–200
  24. Hilbert SL, Yanagida R, Souza J, et al. Prototype anionic detergent technique used to decellularize allograft valve conduits evaluated in the right ventricular outflow tract in sheep. J Heart Valve Dis. 2004;13:831–840
  25. Steinhoff G, Stock U, Karim N, et al. Tissue Engineering of pulmonary heart valves on allogenic acellular matrix conduits. Circulation. 2000;102:SIII50–SIII55
  26. Kasimir MT, Rieder E, Seebacher G, et al. Comparison of different decellularization procedures of porcine heart valves. Int J Artif Organs. 2003;26(5):421–427
  27. Rieder E, Kasimir MT, Silberhumer G, et al. Decellularization protocols of porcine heart valves differ importantly in efficiency of cell removal and susceptibility of the matrix to recellularization with human vascular cells. J Thorac Cardiovasc Surg. 2004;172:399–405
  28. Kasimir MT, Rieder E, Seebacher G, Wolner E, Weigel G, Simon P. Presence and elimination of the Xenoantigen Gal (α1,3)Gal in tissue engineered heart valves. Tissue Eng. 2005;11:1274–1279
  29. Sandrin MS, McKenzie IF. Gal alpha(1,3)Gal, the major xenoantigen (s) recognised in pigs by human natural antibodies. Immunol Rev. 1994;141:169–190
  30. Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH. Immunopathology of hyperacute xenograft rejection in a swine to primate model. Transplantation. 1991;52:214–220
  31. Stone KR, Walgenbach AW, Abrams JT, Nelson J, Gillett N, Galili U. Porcine and bovine cartilage transplants in cynomolgus monkey: I. A model for chronic xenograft rejection. Transplantation. 1997;63:640–645
  32. Konakci KZ, Bohle B, Blumer R, et al. Alpha-Gal on bioprostheses: xenograft immune response in cardiac surgery. Eur J Clin Invest. 2005;35(1):17–23
  33. Murray G. Homologous aortic valve segment transplants for aortic and mitral insufficiency. Angiology. 1956;7:466–471
  34. Heimbecker RO, Aldrige HE, Lemire G. The durability and fate of aortic valve grafts. An experimental study with a long term follow-up of clinical patients. J Cardiovasc Surg (Torino). Nov–Dec 1968;9(6):511–517
  35. Kerwin AG, Lenkei SC, Wilson DR. Aortic valve homograft in the treatment for aortic and mitral insufficiency. N Engl J Med. 1962;266:852–857
  36. Hogan P, Duplock L, Green M, et al. Human aortic valve allografts elicit a donor-specific immune response. J Thorac Cardiovasc Surg. 1996;112(5):1260–1266
  37. Hoekstra FM, Witvliet M, Knoop CY, et al. Immunogenic human leukocyte antigen class II antigens on human cardiac valves induce specific alloantibodies. Ann Thorac Surg. 1998;66(6):2022–2026
  38. Elkins RC, Lane MM, Capps SB, McCue C, Dawson PE. Humoral immune response to allograft valve tissue pretreated with an antigen reduction process. Semin Thorac Cardiovasc Surg. 2001;13(4 Suppl 1):82–86
  39. da Costa FD, Dohmen PM, Duarte D, et al. Immunological and echocardiographic evaluation of decellularized versus cryopreserved allografts during the Ross operation. Eur J Cardiothorac Surg. 2005;27(4):572–578
  40. Bechtel JF, Gellissen J, Erasmi AW, et al. Mid-term findings on echocardiography and computed tomography after RVOT-reconstruction: comparison of decellularized (SynerGraft) and conventional allografts. Eur J Cardiothorac Surg. 2005;27(3):410–415
  41. Elkins RC, Goldstein S, Hewitt CW, et al. Recellularization of heart valve grafts by a process of adaptive remodeling. Semin Thorac Cardiovasc Surg. 2001;13(4 Suppl 1):87–92
  42. Simon P, Kasimir MT, Seebacher G, et al. Early failure of the tissue engineered porcine heart valve Synergraft™ in paediatric patients. Eur J Cardio-Thorac Surg. 2003;23:1002–1006
  43. Kasimir MT, Weigel G, Sharma J, et al. The decellularized porcine heart valve matrix in Tissue Eng: platelet adhesion and activation. Thromb Haemost. 2005;94:562–567
  44. Wagner DD, Burger P. Platelet in inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2003;23:2131–2137
  45. Gorbet MB, Sefton MV. Material-induced tissue factor expression but not CD11b upregulation depends on the presence of platelets. J Biomed Mater Res A. 2003;67(3):792–800
  46. Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood. 1996;88(1):146–157
  47. Wilhelmi MH, Rebe P, Leyh R, Wilhelmi M, Haverich A, Mertsching H. Role of inflammation and ischemia after implantation of xenogeneic pulmonary valve conduits: histological evaluation after 6 to 12 months in sheep. Int J Artif Organs. 2003;26(5):411–420
  48. Caterina MJ, Devreotes PN. Molecular insights into eukaryotic chemotaxis. FASEB J. 1991;5(15):3078–3085
  49. Rieder E, Seebacher G, Kasimir MT, et al. Tissue Engineering of heart valves: decellularized porcine and human valve scaffolds differ importantly in residual potential to attract monocytic cells. Circulation. 2005;111:2792–2797
  50. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407(6801):258–264
  51. Osborn L. Leukocyte adhesion to endothelium in inflammation. Cell. 1990;62:3–6
  52. Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB. 1992;6:2591–2599

PII: S1058-9813(05)00081-0

doi: 10.1016/j.ppedcard.2005.11.004

Progress in Pediatric Cardiology
Volume 21, Issue 2 , Pages 161-165 , March 2006

Article Tools